Skip to search formSkip to main contentSkip to account menu

NCX 4016

Known as: NCX-4016 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2006
Highly Cited
2006
Ovarian cancer is a gynecological malignancy that is commonly treated by cytoreductive surgery followed by cisplatin treatment… 
Review
2006
Review
2006
NCX 4016, 2-(acetyloxy)benzoic acid 3-[(nitrooxy)methyl]phenyl ester, is a new molecule in which a nitric oxide (NO)-releasing… 
Highly Cited
2003
Highly Cited
2003
BACKGROUND AND AIMS NCX-4016 is a nitric oxide-releasing derivative of aspirin with antiplatelet activity. The aim of this study… 
Highly Cited
2002
Highly Cited
2002
Background—NCX-4016 is an acetylsalicylic acid (ASA) derivative containing a nitric oxide–releasing moiety. Compared with ASA… 
2002
2002
We investigated the effect of a nitric oxide (NO)‐releasing derivative of aspirin (NCX‐4016) on a mitochondria‐dependent model of… 
Highly Cited
2001
Highly Cited
2001
NCX 4016, a nitro-ester of aspirin endowed with antithrombotic activity, appears to have clinical potential in treating cardiac…